AccScience Publishing / GTM / Online First / DOI: 10.36922/gtm.2281
Cite this article
50
Download
940
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
CASE REPORT

Anergy as a potential risk factor for squamous cell carcinoma in an immunocompetent patient with diffuse cutaneous leishmaniasis: A case report

Andrés Tirado-Sánchez1* Alexandro Bonifaz2 Sebastián Hernández-Gómez1
Show Less
1 Department of Internal Medicine, Hospital General de Zona 30, Instituto Mexicano del Seguro Social, Mexico City, México
2 Mycology Laboratory, Hospital General de México, Mexico City, México
Global Translational Medicine 2024, 3(1), 2281 https://doi.org/10.36922/gtm.2281
Submitted: 20 November 2023 | Accepted: 24 January 2024 | Published: 20 March 2024
© 2024 by the Author (s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Despite the rarity, leishmaniasis may occur in tandem with malignancy. This co-occurrence contributes to a postulation that anergy to parasite antigens may predispose an infected patient to the development of diffuse cutaneous leishmaniasis and also increase the risk of developing squamous cell carcinoma due to decreased host immune response. We, herein, present a 63-year-old man suffering diffuse cutaneous leishmaniasis that was poorly responsive to treatment. Furthermore, the patient had several nodule-like, infiltrative, and coalescent lesions on his right face. The Montenegro skin test revealed signs of anergy and the biopsy test revealed squamous cell carcinoma (SCC) coexisting with Leishmania sp. Bodies. The patient was given a treatment with amphotericin B and later with radiation therapy, but the tumors showed a poor response to the treatment, and the patient was lost on follow-up. Our observations of the current case highlight the role of a weakening host immune response as a result of diffuse cutaneous leishmaniasis in the development of SCC. Such postulation points to and corroborates the involvement of anergy, a condition probably caused by parasite-induced suppression of the immune response, linking leishmaniasis, and skin malignancy development.

Keywords
Leishmaniasis
Squamous cell carcinoma
Anergy
Immunosuppression
Funding
None.
Conflict of interest
The authors declare that they have no competing interest.
References
  1. Sasidharan S, Saudagar P. Leishmaniasis: Where are we and where are we heading? Parasitol Res. 2021;120(5):1541-1554. doi: 10.1007/s00436-021-07139-2

 

  1. Lopez Y, Arana B, Rizzo N, Duran E, Acosta-Serrano Á, Mendizabal-Cabrera R. A neglected among the neglected: A review of cutaneous leishmaniasis in Guatemala. Trans R Soc Trop Med Hyg. 2023;117(9):609-616. doi: 10.1093/trstmh/trad024

 

  1. Bañuls AL, Bastien P, Pomares C, Arevalo J, Fisa R, Hide M. Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection. Clin Microbiol Infect. 2011;17(10):1451-1461. doi: 10.1111/j.1469-0691.2011.03640.x

 

  1. Pinheiro RO, Pinto EF, Benedito AB, Lopes UG, Rossi- Bergmann B. The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis. An Acad Bras Cienc. 2004;76(3):519-527. doi: 10.1590/s0001-37652004000300006

 

  1. Saidi N, Blaizot R, Prévot G, et al. Clinical and immunological spectra of human cutaneous leishmaniasis in North Africa and French Guiana. Front Immunol. 2023;14:1134020. doi: 10.3389/fimmu.2023.1134020

 

  1. Rashidi S, Fernández-Rubio C, Manzano-Román R, et al. Potential therapeutic targets shared between leishmaniasis and cancer. Parasitology. 2021;148(6):655-671. doi: 10.1017/S0031182021000160

 

  1. Wysong A. Squamous-cell carcinoma of the skin. N Engl J Med. 2023;388:2262-2273. doi: 10.1056/NEJMra2206348

 

  1. Carrillo-Larco RM, Acevedo-Rodriguez JG, Altez- Fernandez C, Ortiz-Acha K, Ugarte-Gil C. Is there an association between cutaneous leishmaniasis and skin cancer? A systematic review. Wellcome Open Res. 2019;4:110. doi: 10.12688/wellcomeopenres.15367.1

 

  1. Morsy TA. Cutaneous leishmaniasis predisposing to human skin cancer: Forty years local and regional studies. J Egypt Soc Parasitol. 2013;43(3):629-648. doi: 10.12816/0006420

 

  1. Armengot-Carbó M, Carmena-Ramón R, Rodrigo- Nicolás B, Ferrando-Marco J. Unsuspected visceral leishmaniasis infiltrating a squamous cell carcinoma. Actas Dermosifiliogr. 2012;103(4):321-323. doi: 10.1016/j.ad.2011.04.016

 

  1. Ouattassi N, Titou A, Hammas N, Kamal D, El Amine El Alami MN. Squamous cell carcinoma associated with an active cutaneous leishmaniasis in immunocompetent patient: Case presentation of an unlikely association and literature-review. Egypt J Otolaryngol. 2022;38:148. doi: 10.1186/s43163-022-00335-6

 

  1. Kopterides P, Mourtzoukou EG, Skopelitis E, Tsavaris N, Falagas ME. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg. 2007;101(12):1181-1189. doi: 10.1016/j.trstmh.2007.08.003

 

  1. Dalgleish AG, O’Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res. 2002;84:231-276. doi: 10.1016/s0065-230x(02)84008-8

 

  1. Christopoulos P, Dopfer EP, Malkovsky M, et al. A novel thymoma-associated immunodeficiency with increased naive T cells and reduced CD247 expression. J Immunol. 2015;194(7):3045-3053. doi: 10.4049/jimmunol.1402805

 

  1. Friedman R, Hanson S, Goldberg LH. Squamous cell carcinoma arising in a Leishmania scar. Dermatol Surg. 2003;29(11):1148-1149. doi: 10.1046/j.1524-4725.2003.29354.x

 

  1. Sinha S, Fernández G, Kapila R, Lambert WC, Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol. 2008;47(12):1263-1270. doi: 10.1111/j.1365-4632.2008.03804.x

 

  1. França-Costa J, Van Weyenbergh J, Boaventura VS, et al. Arginase I, polyamine, and prostaglandin E2 pathways suppress the inflammatory response and contribute to diffuse cutaneous leishmaniasis. J Infect Dis. 2015;211(3):426-435. doi: 10.1093/infdis/jiu455
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: 3060-8600, Published by AccScience Publishing